Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2016

01-11-2016 | Original Article

Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis

Authors: Zhaojia Gao, Run Shi, Kai Yuan, Yong Wang

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

E2F activators (E2F1–3) codify a family of transcription factors (TFs) in higher eukaryotes. E2F activators are involved in the cell cycle regulation and synthesis of DNA in mammalian cells, and their overexpression has been detected in many human cancers. However, their clinical significance has not been deeply researched in non-small-cell lung cancer (NSCLC), and bioinformatics analysis has never been reported to explore their clinical role in NSCLC. In the current study, we investigated the expression and prognostic value of E2F activators in NSCLC patients through the “TCGA datasets” and the “Kaplan-Meier plotter” (KM plotter) database. Hazard ratio (HR), 95 % confidence intervals, and log-rank P were calculated. Compared with normal tissue samples, E2F activators were overexpressed in NSCLC tissues, in lung adenocarcinoma (LUAD) tissues, and in lung squamous cell carcinoma (LUSC) tissues. In NSCLC patients, E2F1 expression was significantly correlated with age, sex, and tumor stage. E2F2 expression was found to be significantly correlated with sex and tumor size. We further demonstrated that E2F1 and E2F2 overexpressions were significantly associated with poor prognosis. In LUAD patients, E2F1 expression was significantly correlated with tumor size and tumor stage. E2F2 expression was significantly correlated with lymph node status and tumor stage. E2F1 and E2F2 overexpression showed a significant association with poor prognosis, while E2F3 overexpression was significantly correlated to better prognosis. In LUSC patients, E2F1 was concluded to be significantly correlated with tumor stage. However, E2F activators were not found to be correlated to prognosis.
Literature
1.
2.
Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61:91–112.CrossRefPubMed
3.
4.
5.
Niklinski J, Niklinska W, Laudanski J, Chyczewska E, Chyczewski L. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer. 2001;34(Suppl 2):S53–8.CrossRefPubMed
6.
Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol. 2002;198:142–56.CrossRefPubMed
7.
Abreu VA, Howard MS. Tumor-suppressor genes, cell cycle regulatory checkpoints, and the skin. N Am J Med Sci. 2015;7:176–88.CrossRef
8.
9.
10.
DeGregori J, Johnson DG. Distinct and overlapping roles for e2f family members in transcription, proliferation and apoptosis. CURR MOL MED. 2006;6:739–48.PubMed
11.
12.
Dimova DK, Dyson NJ. The e2f transcriptional network: old acquaintances with new faces. Oncogene. 2005;24:2810–26.CrossRefPubMed
13.
Li J, Ran C, Li E, Gordon F, Comstock G, Siddiqui H, Cleghorn W, Chen HZ, Kornacker K, Liu CG, Pandit SK, Khanizadeh M, Weinstein M, Leone G, de Bruin A. Synergistic function of e2f7 and e2f8 is essential for cell survival and embryonic development. Dev Cell. 2008;14:62–75.CrossRefPubMedPubMedCentral
14.
Westendorp B, Mokry M, Groot KM, Holstege FC, Cuppen E, de Bruin A. E2f7 represses a network of oscillating cell cycle genes to control s-phase progression. Nucleic Acids Res. 2012;40:3511–23.CrossRefPubMed
15.
Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–81.CrossRefPubMed
16.
Peart MJ, Poyurovsky MV, Kass EM, Urist M, Verschuren EW, Summers MK, Jackson PK, Prives C. Apc/c(cdc20) targets e2f1 for degradation in prometaphase. Cell Cycle. 2010;9:3956–64.CrossRefPubMedPubMedCentral
17.
18.
Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, Nuckolls F, Giangrande P, Wright FA, Field SJ, Greenberg ME, Orkin S, Nevins JR, Robinson ML, Leone G. The e2f1-3 transcription factors are essential for cellular proliferation. Nature. 2001;414:457–62.CrossRefPubMed
19.
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for e2f proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A. 1997;94:7245–50.CrossRefPubMedPubMedCentral
20.
Santos M, Martinez-Fernandez M, Duenas M, Garcia-Escudero R, Alfaya B, Villacampa F, Saiz-Ladera C, Costa C, Oteo M, Duarte J, Martinez V, Gomez-Rodriguez MJ, Martin ML, Fernandez M, Viatour P, Morcillo MA, Sage J, Castellano D, Rodriguez-Peralto JL, de la Rosa F, Paramio JM. In vivo disruption of an rb-e2f-ezh2 signaling loop causes bladder cancer. Cancer Res. 2014;74:6565–77.CrossRefPubMedPubMedCentral
21.
Rennhack J, Andrechek E. Conserved e2f mediated metastasis in mouse models of breast cancer and her2 positive patients. Oncoscience. 2015;2:867–71.PubMedPubMedCentral
22.
Shackney SE, Chowdhury SA, Schwartz R. A novel subset of human tumors that simultaneously overexpress multiple e2f-responsive genes found in breast, ovarian, and prostate cancers. Cancer Inform. 2014;13:89–100.PubMedPubMedCentral
23.
Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the e2f family in human gastrointestinal carcinomas. Int J Cancer. 1999;81:535–8.CrossRefPubMed
24.
Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H. E2f1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res. 2007;13:6938–46.CrossRefPubMed
25.
Chen L, Yu JH, Lu ZH, Zhang W. E2f2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma. Int J Clin Exp Pathol. 2015;8:10545–54.PubMedPubMedCentral
26.
Cooper CS, Nicholson AG, Foster C, Dodson A, Edwards S, Fletcher A, Roe T, Clark J, Joshi A, Norman A, Feber A, Lin D, Gao Y, Shipley J, Cheng SJ. Nuclear overexpression of the e2f3 transcription factor in human lung cancer. Lung Cancer. 2006;54:155–62.CrossRefPubMed
27.
Tomczak K, Czerwinska P, Wiznerowicz M. The cancer genome atlas (tcga): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:A68–77.
28.
Guo Y, Sheng Q, Li J, Ye F, Samuels DC, Shyr Y. Large scale comparison of gene expression levels by microarrays and rnaseq using tcga data. PLoS One. 2013;8:e71462.CrossRefPubMedPubMedCentral
29.
Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337.
30.
Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
31.
Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241.CrossRefPubMedPubMedCentral
32.
Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.CrossRefPubMed
33.
Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19:197–208.CrossRefPubMed
34.
Xu MM, Mao GX, Liu J, Li JC, Huang H, Liu YF, Liu JH. Low expression of the FoxO4 gene may contribute to the phenomenon of EMT in non-small cell lung cancer. Asian Pac J Cancer Prev. 2014;15:4013–8.CrossRefPubMed
35.
Hung JJ, Hsueh CT, Chen KH, Hsu WH, Wu YC. Clinical significance of E2F1 protein expression in non-small cell lung cancer. Exp Hematol Oncol. 2012;1:18.CrossRefPubMedPubMedCentral
36.
Tai MC, Kajino T, Nakatochi M, Arima C, Shimada Y, Suzuki M, Miyoshi H, Yatabe Y, Yanagisawa K, Takahashi T. Mir-342-3p regulates MYC transcriptional activity via direct repression of E2F1 in human lung cancer. Carcinogenesis. 2015;36:1464–73.PubMed
37.
Gu Y, Cheng Y, Song Y, Zhang Z, Deng M, Wang C, Zheng G, He Z. MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1. PLoS One. 2014;9:e102602.CrossRefPubMedPubMedCentral
38.
Volm M, Koomagi R, Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer. 1998;79:294–9.CrossRefPubMed
39.
Ivey-Hoyle M, Conroy R, Huber HE, Goodhart PJ, Oliff A, Heimbrook DC. Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F. Mol Cell Biol. 1993;13:7802–12.CrossRefPubMedPubMedCentral
40.
DeGregori J. The genetics of the E2F family of transcription factors: shared functions and unique roles. Biochim Biophys Acta. 2002;1602:131–50.PubMed
41.
Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, Marth C, Zeimet AG. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci. 2006;1091:270–81.CrossRefPubMed
42.
Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Muller-Holzner E, Marth C, Zeimet AG. Clinical relevance of E2F family members in ovarian cancer—an evaluation in a training set of 77 patients. Clin Cancer Res. 2007;13:144–51.CrossRefPubMed
43.
Zhan L, Huang C, Meng XM, Song Y, Wu XQ, Miu CG, Zhan XS, Li J. Promising roles of mammalian E2Fs in hepatocellular carcinoma. Cell Signal. 2014;26:1075–81.CrossRefPubMed
44.
He Y, Armanious MK, Thomas MJ, Cress WD. Identification of E2F-3B, an alternative form of E2f-3 lacking a conserved n-terminal region. Oncogene. 2000;19:3422–33.CrossRefPubMed
45.
Leone G, Nuckolls F, Ishida S, Adams M, Sears R, Jakoi L, Miron A, Nevins JR. Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by RB proteins. Mol Cell Biol. 2000;20:3626–32.CrossRefPubMedPubMedCentral
46.
Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol. 2000;20:3633–9.CrossRefPubMedPubMedCentral
47.
Feber A, Clark J, Goodwin G, Dodson AR, Smith PH, Fletcher A, Edwards S, Flohr P, Falconer A, Roe T, Kovacs G, Dennis N, Fisher C, Wooster R, Huddart R, Foster CS, Cooper CS. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene. 2004;23:1627–30.CrossRefPubMed
48.
Oeggerli M, Tomovska S, Schraml P, Calvano-Forte D, Schafroth S, Simon R, Gasser T, Mihatsch MJ, Sauter G. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene. 2004;23:5616–23.CrossRefPubMed
49.
Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene. 2004;23:5871–9.CrossRefPubMed
Metadata
Title
Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis
Authors
Zhaojia Gao
Run Shi
Kai Yuan
Yong Wang
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5389-z

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue

Review

Natural products against cancer angiogenesis

Original Article

Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma

Original Article

Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation

Original Article

Low expression of DCXR protein indicates a poor prognosis for hepatocellular carcinoma patients

Original Article

MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1

Original Article

NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits